Healthcare winners: HCA Holdings Inc (NYSE:HCA), Community Health Systems (NYSE:CYH), Universal Health Services (NYSE:UHS), Uniqure NV (NASDAQ:QURE)

Given the lack of management expertise and synergies, Wesfarmers could struggle to justify offering more for Healthscope than other mooted bidders, which include US healthcare company HCA Holdings Inc (NYSE:HCA), Chinese conglomerate Fosun Pharma and Malaysia’s IHH. HCA Holdings Inc (NYSE:HCA) stock performance was 5.76% in last session and finished the day at $53.44. Traded volume was 7.66million shares in the last session and the average volume of the stock remained 2.54million shares. The beta of the stock remained 1.69. HCA Holdings Inc (NYSE:HCA) insider ownership is 29.40%.

Shares of Community Health Systems (NYSE:CYH) have been given an average rating of “Buy” by the twenty-one brokerages that are covering the stock, Analyst Ratings Net reports. Six analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. Community Health Systems (NYSE:CYH) rose 6.60 percent to $39.92 Friday on volume of 2.69million shares. The intra-day range of the stock was $37.85 to $40.08. Community Health Systems (NYSE:CYH) has a market capitalization of $4.60billion.

Universal Health Services, Inc. (NYSE:UHS) announced today that its reported net income attributable to UHS was $138.1 million, or $1.38 per diluted share, during the first quarter of 2014 as compared to $119.8 million, or $1.21 per diluted share, during the comparable quarter of 2013. Universal Health Services, Inc. (NYSE:UHS)’s stock on Apr 25, 2014 reported a increase of 6.14% to the closing price of $82.92. Its fifty two weeks range is $63.51 -$86.08. The total market capitalization recorded $8.18billion. The overall volume in the last trading session was 1.71million shares. In its share capital, UHS has 98.75million outstanding shares.

The company behind Glybera, Uniqure NV (NASDAQ:QURE), has a series of other gene therapies undergoing clinical testing as well. Uniqure NV (NASDAQ:QURE)’s targets include diseases such as acute intermittent porphyria, Parkinson’s disease, and Sanfilippo syndrome. On Friday, shares of Uniqure NV (NASDAQ:QURE) advanced 8.37% to close the day at $11.00. Company monthly performance is recorded as -30.95%.